Key result
Enoxaparin was at least as efficacious as standard unfractionated heparin for deep-vein thrombosis prophylaxis in high-risk hospitalized medical patients, with fewer adverse events.
Why the study?
Does enoxaparin (40 mg) prevent deep-vein thrombosis compared to standard unfractionated heparin in high-risk hospitalized medical patients?
Does enoxaparin (40 mg) prevent deep-vein thrombosis compared to standard unfractionated heparin in high-risk hospitalized medical patients?
Enoxaparin is an effective and safer alternative to standard unfractionated heparin for DVT prophylaxis in high-risk hospitalized medical patients.
No takes yet. Share an insight, caveat, or question.
Supports enoxaparin preference for DVT prophylaxis in high-risk medical inpatients; confirms noninferior efficacy with superior safety versus unfractionated heparin.
Lechler et al. (2009) studied this question. Enoxaparin was at least as efficacious as standard unfractionated heparin for deep-vein thrombosis prophylaxis in high-risk hospitalized medical patients, with fewer adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: